Mizuho Securities analyst Vamil Divan reiterated a Buy rating on Axsome Therapeutics (NASDAQ:AXSM) Inc on Monday, setting a price target of $118, which is approximately 107.16% above the present share price of $56.96.
Divan expects Axsome Therapeutics Inc to post earnings per share (EPS) of -$0.78 for the second quarter of 2021.
The current consensus among 6 TipRanks analysts is for a Strong Buy rating of shares in Axsome Therapeutics, with an average price target of $144.
The analysts price targets range from a high of $225 to a low of $104.
In its latest earnings report, released on 12/31/2020, the company reported a quarterly revenue of $0 and a net profit of -$27.69 million. The company's market cap is $2.14 billion.
According to TipRanks.com, Mizuho Securities analyst Vamil Divan is currently ranked with 1 stars on a 0-5 stars ranking scale, with an average return of -1.2% and a 49.54% success rate.
Axsome Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing novel therapies for the management of central nervous system disorders. Its product candidates include AXS-02 and AXS-06 which are developing for multiple indications. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.